Degradation of vincristine by myeloperoxidase and hypochlorous acid in children with acute lymphoblastic leukemia

Basit Öğe Kaydı
dc.authoridTürköz, Yusuf/0000-0001-5401-0720
dc.authoridAslan, Mehmet/0000-0001-5710-6592
dc.authorwosidTürköz, Yusuf/ABG-7931-2020
dc.authorwosidAslan, Mehmet/AEL-7823-2022
dc.contributor.authorÖzgen, O
dc.contributor.authorTürköz, Y
dc.contributor.authorStout, M
dc.contributor.authorÖzugurlu, F
dc.contributor.authorPelik, F
dc.contributor.authorBulut, Y
dc.contributor.authorAslan, M
dc.date.accessioned2024-08-04T20:13:22Z
dc.date.available2024-08-04T20:13:22Z
dc.date.issued2003
dc.departmentİnönü Üniversitesien_US
dc.description.abstractVincristine (VCR) is an effective drug against acute lymphoblastic leukemia (ALL), many solid tumors, but not acute myeloid leukemia. It has been hypothesized that resistance of myeloblasts to VCR is related to myeloperoxidase (MPO) and production of hypochlorous acid (HOCl). We investigated the relationship between VCR degradation and MPO expression and serum HOCl concentrations in pediatric patients with ALL, lymphoma and solid tumors. We studied the sera from 43 children, of which 23 were newly diagnosed and as yet untreated cancer patients, 10 on chemotherapy and 10 healthy control subjects. Patients' sera were incubated with VCR alone or in the presence of taurine (T) or acetaminophen (APAP) and post-incubation VCR and HOCL concentrations were measured. Significant correlations between serum MPO expression, HOCl concentrations and VCR degradation were seen. In the chemotherapy group, MPO-positive patients produced high levels of HOCl and reciprocally low post-incubation VCR levels. HOCl and VCR concentrations in this group were significantly different than other groups studied. Both APAP and T inhibited VCR degradation in the sera of the chemotherapy group but not to the same degree. The effects seen here were consistent for both ALL and the lymphoma/solid tumor cases. Our results indicate that HOCl can increase VCR degradation in vitro in the serum and this effect is significantly more pronounced in pediatric patients undergoing chemotherapy. (C) 2003 Elsevier Science Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/S0145-2126(03)00098-5
dc.identifier.endpage1113en_US
dc.identifier.issn0145-2126
dc.identifier.issue12en_US
dc.identifier.pmid12921949en_US
dc.identifier.scopus2-s2.0-0041663665en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage1109en_US
dc.identifier.urihttps://doi.org/10.1016/S0145-2126(03)00098-5
dc.identifier.urihttps://hdl.handle.net/11616/93584
dc.identifier.volume27en_US
dc.identifier.wosWOS:000185431400009en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofLeukemia Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectvincristine metabolismen_US
dc.subjectmyeloperoxidaseen_US
dc.subjecthypochlorous aciden_US
dc.subjectleukemiaen_US
dc.titleDegradation of vincristine by myeloperoxidase and hypochlorous acid in children with acute lymphoblastic leukemiaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu